Evidence map›Paper›PMID 21567080›Full record

ArticleInternational journal of oncology2011

Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts.

Olivier DE Wever, Joëlle Sobczak-Thépot, Anne-Sophie Vercoutter-Edouart, Jean-Claude Michalski, Radia Ouelaa-Benslama, Dwayne G Stupack, Marc Bracke, Jean Y J Wang, Christian Gespach, Shahin Emami

Open access · bronzeAbstract read
In one paragraph

Article in International journal of oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Advances in research on the interaction between inflammation and cancer.The Journal of international medical research · 2020
    Review
  3. Article
  4. Review
  5. Article
  6. Isolation of primary myofibroblasts from mouse and human colon tissue.Journal of visualized experiments : JoVE · 2013
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Olivier DE WeverLaboratory of Experimental Cancerology, Ghent University Hospital, Ghent, Belgium.
Joëlle Sobczak-ThépotCNRS UMR 7098, Paris.
Anne-Sophie Vercoutter-EdouartUnité de Glycobiologie Structurale et Fonctionnelle UMR USTL/CNRS no. 8576 - IFR147, Villeneuve-d'Ascq, France.
Jean-Claude MichalskiUnité de Glycobiologie Structurale et Fonctionnelle UMR USTL/CNRS no. 8576 - IFR147, Villeneuve-d'Ascq, France.
Radia Ouelaa-BenslamaINSERM U673 and U938, Laboratory of Cancer Biology and Therapeutics, Centre de recherche Saint-Antoine.
Dwayne G StupackMoores UCSD Cancer Center, UCSD School of Medicine, La Jolla, CA, USA.
Marc BrackeLaboratory of Experimental Cancerology, Ghent University Hospital, Ghent, Belgium.
Jean Y J Wang *Moores UCSD Cancer Center, UCSD School of Medicine, La Jolla, CA, USA.
Christian Gespach *INSERM U673 and U938, Laboratory of Cancer Biology and Therapeutics, Centre de recherche Saint-Antoine.
Shahin EmamiINSERM U673 and U938, Laboratory of Cancer Biology and Therapeutics, Centre de recherche Saint-Antoine.
Ghent University Hospital · BE

Funding

TYROSINE KINASE C-ABL AND BCR-ABL IN INTEGRIN DEPENDENT SIGNALINGP01HL057900 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHATTIL, SANFORD J · 1997 to 2012
$17.4M
STRUCTURE AND FUNCTION OF THE C-ABL PROTO-ONCOPROTEINR01CA043054 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WANG, JEAN Y.J. · 1986 to 2018
$4.4M
NCI NIH HHS R01 CA043054NHLBI NIH HHS P01 HL057900
6 · The paper itself

Abstract

We have previously shown that the genotoxin-induced apoptosis in mouse embryo fibroblasts was enhanced by the extracellular matrix protein fibronectin (FN). In the present study, we tested the hypothesis that FN regulates the DNA damage response (DDR) signaling pathways in HCT116 (p53-wt) and HT29 (p53-mut) human colon cancer cells and tumor-derived myofibroblasts. DNA damage recognition mechanisms were analyzed by immunofluorescence staining, cell cycle analysis and immunoblotting addressed at specific molecular sensors and executors involved in the DDR pathways. The results show that FN, but not collagen type IV or Matrigel, initiates and potentiates the DDR to the anticancer drug cisplatin in an α5 integrin and cell cycle-dependent manner (S and G2/M phases) in human colon cancer cells. Accordingly, we demonstrate that adhesion of HCT116 cells to FN upregulated the expression of α5 integrin FN receptors at the cell surface. These FN-induced DDR pathways include the concerted phosphorylation of histone H2AX on Ser139 detected as nuclear foci (γ-H2AX, 15 and 25 kDa forms), of ataxia telangiectasia mutated (ATM-Ser1981), checkpoint kinase 2 (CHK2-Thr68, 62 and 67 kDa) and p53-Ser15. These FN-induced γ-H2AX signals were interrupted or attenuated by selective inhibitors acting on the DDR pathway kinases, including wortmannin (targeting the phosphatidylinositol-3-kinase-related protein kinases, PIKK), KU55933 (ATM), NU7026 (DNA-dependent protein kinase catalytic subunit, DNA-PK-cs) and SP600125 (JNK2, stress activated protein kinase/c-Jun N-terminal kinase-2). Adhesion to FN also potentiated the γ-H2AX signals and the cytotoxic effects of cisplatin in human colon tumor-derived myofibroblasts. These data provide evidence that FN promotes DNA damage recognition and chemosensitization to cisplatin via the potentiation of the DNA damage signaling responses in human colon cancer cells and tumor-derived myofibroblasts.

Indexed as

Cell AdhesionCell CycleCell Line, TumorCell ProliferationCheckpoint Kinase 2CisplatinColonic NeoplasmsCross-Linking ReagentsDNA DamageFibronectinsHCT116 CellsHistonesHT29 CellsHumansMyofibroblastsPhosphorylationCheckpoint Kinase 2CHEK2 protein, humanChek2 protein, mouseCisplatinCross-Linking ReagentsFibronectinsH2AX protein, humanHistonesProtein Serine-Threonine KinasesReceptors, Fibronectin

Identifiers

PMID21567080
PMCPMC5003111
OpenAlexW1970078088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.